Breakout Labs

Breakout Labs was founded by the Thiel Foundation in 211 and is based in San Francisco CA. Breakout Labs provides seed grants of $35 to 8-1 early stage companies per year. Companies must reach specific milestones in order to receive installments of the grant. Breakout Labs grants are in the form of a convertible note that if the company raises a Series A round will convert based on the Series A valuation, however if the company fails before raising a Series A round no debt will be due. Additionally when a portfolio company becomes revenue-generating or is acquired Breakout Labs receives a 3% royalty payment capped at 3x the value of the grant. Breakout Labs funds companies throughout the USA.
Lindy Fishburne
Executive Director 
Michelle Kim-Danely
Portfolio Manager 

Broadview Ventures

Broadview Ventures is a Philanthropy Venture firm that was established by the Leducq Family Trust in 28 and dedicated to accelerating the translation of new and innovative programs in the CV and stroke areas. The firm is based out of Boston MA but is geographically agnostic in its investing. The firm makes equity and convertible note investments of approximately $1 million into companies that are targeting cardiovascular and neurovascular diseases. The firm invests in privately held companies at both the seed and venture stage and is currently invests in 4-5 companies per year. The firm operates under an evergreen structure and is constantly seeking new investment opportunities. While the firm will consider investments around the globe Broadview is keen to add companies based in Europe to its portfolio. Broadview has previously invested in the US Europe and Israel.
Maria Berkman
Director 
Rick Jones
Director 
Christopher de Souza
Director 

Celling Biosciences United States

Regeneration Through Innovation

Celling Biosciences is dedicated to researching and developing the future of healing through regenerative medicine and the clinical use of autologous regenerative cells to facilitate the body’s capacity to heal itself. Through our patented Celling therapies and our Institutes of Regenerative Medicine, Celling Biosciences is moving the science of healing forward and redefining the global medical landscape.

Year Founded
2006
Biotech Subsector
Biotech Phase of Development
Medtech Phase of Development
Technology Overview
Regeneration Through Innovation

Celling Biosciences is dedicated to researching and developing the future of healing through regenerative medicine and the clinical use of autologous regenerative cells to facilitate the body’s capacity to heal itself. Through our patented Celling therapies and our Institutes of Regenerative Medicine, Celling Biosciences is moving the science of healing forward and redefining the global medical landscape.

Current Financing Needs

$3-10 million growth capital with opportunity for partial founder buy-out.

Management Team Highlights
Kevin Dunworth

Founder / CEO

Kevin Dunworth, Founder of Celling Biosciences, has spent more than 26 years in the orthopedic industry and brings a wealth of expertise in all aspects of the business. Dunworth has run medical companies in the Middle East, Eastern and Western Europe, and the United States.

He excelled in various executive positions before founding VCD Medical, in Austin, Texas.
For the past eight years, Dunworth has successfully built a world-class distribution business, which provides a variety of orthopedic and biologic products.

Dunworth's leadership roles within the orthopedic industry have included, Director of Emerging Markets and Director of European Sales for Smith & Nephew; Director of International Sales, Vice President of Worldwide Sales and Vice President for FlouroScan International and Vice President of Sales for TransLeasing and Vice President for TransLeasing GE.


Steve Melchiode

President
Steve Melchiode has extensive experience guiding businesses from start-up to profitability. After earning an undergraduate marketing degree followed by a law degree, Melchiode joined a start-up technology firm in Silicon Valley as the West Coast business development director. Melchiode's ability to build and lead successful companies, combined with his experience in medical device sales, provides him with the vision and expertise to lead the Celling Biosciences team. He brings a wide range of experience in sales, business development, marketing, finance, legal and operations management.

Melchiode began his medical device career as a sales representative with VCD Medical, learning the spinal implant industry selling Depuy Spine. After two years spent growing several new territories, Melchiode established himself in a leadership role as sales manager and by running operations for the State of Texas. For the past two years, he has worked with Kevin Dunworth to take the Celling Biosciences model from concept to market, working on business, product and partnership development as well as marketing and operations.

Mr Blair Duncan
Mr Blair Duncan
LinkedIn logo Chief Financial Officer 
BIO

Blair Duncan, Chief Financial Officer, Celling Biosciences

 

Mr. Duncan has over 20 years experience in venture-backed growth companies, as well as Fortune 500 and service firms. Before joining Celling Biosciences, Mr. Duncan was Chief Financial Officer at Emergent Technologies, an early stage life sciences commercialization operator and venture capital firm.  Previously, Mr. Duncan was Chief Financial Officer and Controller at SiteStuff, a leading provider of online procurement services for the commercial real estate industry.  Prior to SiteStuff, Mr. Duncan was Chief Financial Officer for Trillion, a facilities-based provider of wireless broadband telecommunications services to K-12 school districts.  Mr. Duncan also served as Vice President and Controller for ClearSource, a facilities-based provider of broadband telecommunications services.  Mr. Duncan held positions at PricewaterhouseCoopers as Manager of Entrepreneurial Advisory Services, where he launched a new division providing fundraising and business planning consulting services to high-tech companies in Texas, as well as Manager in the Business Assurance practice, where he participated in numerous public offerings and private company audits.  Mr. Duncan started his career with Aetna as a manager of property and casualty underwriting and business development. 

 

Mr. Duncan is a CPA and holds a MBA from the University of Texas at Austin.  He has a BA in Economics and Psychology from Duke University. Mr. Duncan enjoys travel, music, tennis and golf.  He is Career Services Chair of the Financial Executives International – Austin Chapter, as well as Treasurer of the Maya Exploration Center.  He is married with three children and resides in Austin, Texas.

Chempetitive Group

Chempetitive Group is an integrated marketing communications agency focused exclusively on the life sciences. We work with biotech, medical device, pharmaceutical, chemical and tools/instrumentation companies of all sizes that around the globe. We develop winning strategies and campaigns that build brands and generate revenues. We love science. We understand science. And, we know how to effectively reach the scientific, clinical, medical and business communities that matter. 

Long live science. 

Visit us in San Diego, San Francisco, Chicago, Boston or Cambridge UK. 

Find out about us at http://www.chempetitive.com 

Erik Clausen
Erik Clausen
LinkedIn logo Managing Partner 
BIO

Erik Clausen is a managing partner at Chempetitive Group (http://www.chempetitive.com), a marketing communications firm that develops and implements strategies and drives results for life science and healthcare companies. Erik brings two decades of international experience helping life science, medical technology and healthcare organizations to reach and engage the right audiences.

Chiesi Ventures

Chiesi Ventures is a Venture Capital firm formed by a partnership between the Italian Pharmaceutical company Chiesi and US based VC firm Pappas Ventures. The firm is currently looking to make seed and venture stage investments into companies ranging anywhere from $2K to $5 million initially and up to $8 million over the life of the investment. The firm is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.
Art Pappas
Partner 

CitareTx Investment Partners

CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.

Jeffery Sheldon
General Partner & Managing Director 

Correlation Ventures United States

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

Year Founded
2010
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
David Coats
Managing Director 

Diamond BioFund Taiwan

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Winston Town
Vice President 
Haolin Sung
LinkedIn logo Director 

DreamCatcher Ventures United States

  

Tania Fernandez is the founder of Dream Catcher Ventures, an advisory firm founded to address the inefficiencies in the marketplace and to align the goals and aspirations of entrepreneurs with investors in the healthcare/biotech sector. It is focused on creating and building disruptive biotech/healthcare companies that are positioned to excel in global markets. The firm also has a strong focus on biotech companies that have assets/technologies that are relevant to the Indian market.

Dr. Fernandez is currently working with BioHealth Innovation on a $50M “Gap Fund” to invest in seed and early stage healthcare/biotech companies primarily in therapeutics, diagnostics, medtech and healthcare IT.

Tania has a doctorate in molecular oncology and a post doctorate in protein chemistry and genetic engineering. She has over fifteen years of experience in the life sciences and 10 years of venture capital investing experience in biotech/ life sciences/healthcare and healthcare delivery.

Tania Fernandez
Founder